A nanovesicle and its preparation method and application
By using nanovesicle technology in TC-DAPK6 drugs, using macrophage membranes and hollow mesoporous silica nanoparticles as carriers, the problem of drugs passing through the blood-brain barrier is solved, and precise treatment of nerve cell damage is achieved. Reduces side effects and improves therapeutic effects.
Patent Information
- Application Number
- CN202311256289.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-09-26
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2043-09-26
AI Technical Summary
The prior art is difficult to effectively pass TC-DAPK6 drugs through the blood-brain barrier. Direct administration has problems such as fast drug metabolism, poor blood-brain barrier permeability and many side effects, which limits its application in the treatment of neurological diseases.
Nanovesicles are used as drug-loading system, macrophage membranes are used as membranes and hollow mesoporous silica nanoparticles are used as cores, and the carrier is loaded with TC-DAPK6, and nanovesicles are prepared through micro-liposome extrusion technology to realize the target of the drug. Delivery to.
The targeted delivery of TC-DAPK6 in brain was achieved, reducing inflammatory response and apoptosis in nerve cell damage, significantly improving the therapeutic effect, and having low toxicity and good biocompatibility.
Smart Images

Figure BDA0004472510080000011 
Figure BDA0004472510080000081 
Figure HDA0004472510100000011
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biopharmaceutical technology, and in particular to a nanocapsule and a preparation method and application thereof. Background Art
[0002] Central nervous system diseases usually include acute brain injury and chronic neurodegenerative diseases. These diseases are often accompanied by neuronal damage, affecting the neuronal structure and function of the brain. Therefore, it is of great significance to actively seek effective molecular targets for the treatment of neuronal damage and develop drug delivery systems that can effectively penetrate the blood-brain barrier and target brain lesions.
[0003] Death-associated protein kinase 1 (DAPK1) is a calcium / calmodulin-dependent serine / threonine kinase. Abnormal expression of DAPK1 is upregulated in neurological diseases such as Alzheimer's disease, epilepsy, depression and stroke, and brain tissue damage can be alleviated by ablation of DAPK1 gene expression or inhibition of DAPK1 activity. The molecular formula of TC-DAPK6 is C 17 H 12 N 2 O 2 , molecular weight is 276.29, structural formula is as follows:
[0004]
[0005] TC-DAPK6 is the most effective small molecule inhibitor of DAPK1 obtained through structure-based virtual screening and identification. It is a promising drug molecule for treating neuronal cell damage by inhibiting DAPK1. However, DAPK1 is expressed in various tissues such as the heart, lungs, spleen and brain, and is involved in mediating physiological or pathological processes such as apoptosis, autophagy, inflammation, oxidative stress, neurogenesis, neuronal damage and synaptic transmission. How to deliver TC-DAPK6 to neuroinflammatory lesions in the brain is an urgent problem to be solved.
[0006] Direct administration of TC-DAPK6 (such as intraperitoneal injection) has disadvantages such as rapid drug metabolism, poor blood-brain barrier permeability and many side effects, making it difficult to exert precise therapeutic effects on nerve cell damage.
[0007] Loading drug molecules into nanoparticles can protect drugs from being easily hydrolyzed by enzymes, improve drug stability, and prolong blood circulation time. However, as foreign materials in organisms, nanoparticles are easily cleared by the liver, kidneys, and immune system, and have low permeability to the blood-brain barrier, which limits their application in the treatment of neurological diseases.
[0008] In view of this, the present invention is proposed. Summary of the invention
[0009] In order to solve the above technical problems, the present invention provides a nanovesicle and a preparation method and application thereof, so as to effectively solve the problem of targeted delivery and therapeutic medication of TC-DAPK6 to inflammatory lesions in the brain.
[0010] The invention provides a nanovesicle, the membrane of the nanovesicle is the cell membrane of a macrophage, the inner core of the nanovesicle is a drug-loaded nanoparticle, the drug-loaded nanoparticle uses a hollow mesoporous silica nanoparticle as a carrier, and the carrier is loaded with a death-associated protein kinase 1 inhibitor TC-DAPK6.
[0011] Optionally, the carrier is also loaded with a fluorescent dye, and the fluorescent dye is selected from rhodamine B or fluorescein isothiocyanate.
[0012] Optionally, the diameter of the nanovesicle is 60nm to 150nm, preferably 80nm to 100nm; the diameter of the hollow mesoporous silica particles is 70nm to 90nm.
[0013] The present invention provides a method for preparing the nanovesicles, which comprises at least the following steps:
[0014] S1. Dispersing hollow mesoporous silica nanoparticles in an organic solvent, adding death-associated protein kinase 1 inhibitor TC-DAPK6, stirring, separating, washing, and drying to obtain drug-loaded nanoparticles; wherein the mass ratio of the hollow mesoporous silica nanoparticles to the death-associated protein kinase 1 inhibitor TC-DAPK6 is 4 to 1:1;
[0015] S2, separation and acquisition of macrophage membrane;
[0016] S3. The drug-loaded nanoparticles and macrophage membranes are mixed in a buffer solution to obtain a mixed solution, and the mixed solution is extruded through porous membranes with pore sizes of 400 nm and 200 nm in sequence 12 to 18 times using a micro-liposome extruder to obtain nanovesicles.
[0017] Optionally, in S1, the volume of each mg of hollow mesoporous silica nanoparticles dispersed in the organic solvent is 2 mL to 4 mL, the organic solvent is selected from anhydrous ethanol, the stirring time is 8 to 14 hours, and the rotation speed is 500 to 700 rpm.
[0018] Optionally, in S1, hollow mesoporous silica nanoparticles are dispersed in an organic solvent, and death-associated protein kinase 1 inhibitor TC-DAPK6 and a fluorescent dye are added, and the mass ratio of the hollow mesoporous silica nanoparticles, the death-associated protein kinase 1 inhibitor TC-DAPK6 and the fluorescent dye is 2:2:1 to 1:1:1.
[0019] Optionally, in S1, separation is performed by centrifugation, washing is performed by anhydrous ethanol for 2 to 4 times, and the drying time is 8 to 12 hours.
[0020] Optionally, in S3, the mass ratio of the drug-loaded nanoparticles to the macrophage membrane is 2:1 to 1:2; and the concentration of the drug-loaded nanoparticles is 0.5 mg / mL to 1 mg / mL.
[0021] The present invention provides application of the nanovesicles in preparing medicine for treating nerve cell damage.
[0022] The present invention provides a brain-targeted preparation containing the nanovesicles.
[0023] The technical solution provided by the present invention has the following advantages compared with the prior art:
[0024] The present invention proposes a nanovesicle, which is a biomimetic nanoparticle, with drug-loaded nanoparticles as the core and macrophage cell membrane as the membrane to coat the drug to form a core-shell structure. It has the technical advantages of small particle size, low toxicity, and the ability to penetrate the blood-brain barrier. It specifically inhibits death-associated protein kinase 1 (DAPK1) in inflammatory lesions, and exerts a therapeutic effect on nerve cell damage by alleviating inflammatory reactions and reducing nerve cell apoptosis.
[0025] The nanovesicles of the present invention provide a novel brain targeted drug delivery system for treating nerve cell damage, and can deliver TC-DAPK6 to the inflammatory site in the brain in a targeted manner. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 This is a photo of Dio cell membrane fluorescence staining of RAW264.7 macrophages;
[0027] Figure 2 TEM images of RT-HMSN and MA@RT-HMSN;
[0028] Figure 3 The particle size statistics of RT-HMSN and MA@RT-HMSN;
[0029] Figure 4 Zeta potential analysis results of RT-HMSN and MA@RT-HMSN;
[0030] Figure 5 PXRD results of RT-HMSN and MA@RT-HMSN;
[0031] Figure 6 , Figure 7 The cell membrane protein characterization results of MA@RT-HMSN;
[0032] Figure 8 Cytotoxicity results of RT-HMSN and MA@RT-HMSN;
[0033] Fig. 9 Cell fluorescence imaging results of MA@RT-HMSN;
[0034] Fig.10 Statistical analysis results of cell fluorescence imaging of MA@RT-HMSN;
[0035] Fig.11 The results of the effect of RT-HMSN on the cell viability of HT22 cells;
[0036] Fig.12 The results show the effect of RT-HMSN on the relative mRNA expression of DAPK1 and inflammatory factors in HT22 cells;
[0037] Fig.13 The results of RT-HMSN immunoblotting of DAPK1 and NLRP3 proteins in HT22 cells;
[0038] Fig.14 The statistical analysis results of the relative expression of DAPK1 protein in HT22 cells by RT-HMSN;
[0039] Fig.15 The statistical analysis results of the relative expression of NLRP3 protein in HT22 cells by RT-HMSN;
[0040] Fig.16 , Fig.17 The results of the experiment on the inhibitory effect of RT-HMSN on HT22 cell apoptosis;
[0041] Fig.18 The results of in vitro blood-brain barrier permeability and targeting experiments of MA@RT-HMSN. DETAILED DESCRIPTION
[0042] In order to more clearly understand the above-mentioned purposes, features and advantages of the present invention, the scheme of the present invention will be further described below. It should be noted that the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict. In the following description, many specific details are set forth to facilitate a full understanding of the present invention, but the present invention can also be implemented in other ways different from those described herein; obviously, the embodiments in the specification are only part of the embodiments of the present invention, not all of the embodiments.
[0043] In view of the technical problem that direct administration of the death-related protein kinase 1 inhibitor TC-DAPK6 cannot achieve a therapeutic effect on nerve cell damage, the embodiment of the present invention proposes a preparation with targeting and blood-brain barrier permeability, which not only achieves the conditional targeting of TC-DAPK6 without degradation through the blood-brain barrier, but also can achieve precise therapeutic effects on nerve cell damage in the brain. In order to achieve the above-mentioned invention purpose, the embodiment of the present invention proposes a nanovesicle, which is a core-shell structure, with drug-loaded nanoparticles as the core, and uses the cell membrane of macrophages as the membrane of the nanovesicle, and the core is coated. Macrophages are phagocytic cells of the innate immune system in the body, which can not only respond to biological signals and show natural tropism to inflammatory sites, but also can adhere to and pass through vascular endothelial cells and cross the blood-brain barrier. Therefore, the embodiment of the present invention uses macrophage membranes to coat drug-loaded nanoparticles, which can not only make nanoparticles better adapt to complex physiological environments and increase biocompatibility, but also improve their ability to penetrate the blood-brain barrier and deliver the loaded drugs to the inflammatory sites in the brain.
[0044] First, since the purpose of the present invention is to be applied to the treatment of brain diseases, the literature reports that most brain diseases are accompanied by inflammatory reactions. Macrophages are phagocytic cells of the body's natural immune system. Macrophage membrane proteins retain the uniqueness of macrophages, have surface receptor chemotaxis, show natural tropism to inflammatory sites, and can adhere to and pass through vascular endothelial cells, across the blood-brain barrier, and when brain inflammatory factors increase, macrophages in the circulation can be recruited to cross the blood-brain barrier to the inflammatory site, achieving the effect of targeting brain inflammatory lesions. Compared with red blood cell membranes, stem cell membranes, cancer cell membranes, nerve cell membranes and liposomes, it has obvious application advantages.
[0045] Regarding the choice of carrier, compared with mesoporous materials, hollow mesoporous materials have a higher loading capacity. TC-DAPK6 is a hydrophobic compound containing an ester group. It is not easy to load by means of functional group binding, and it is easier to enter the interior of the carrier with pores by physical means. The synthesis technology of hollow mesoporous silica is mature, the method is simple, and it is easy to obtain. In addition, the synthesis method of loading TC-DAPK6 by physical adsorption is simple, the loading capacity is large, and it is stable and repeatable, which has obvious advantages. In order to ensure good blood-brain barrier permeability, the embodiment of the present invention needs to control the diameter of the nanovesicles within 150nm, and further preferably within 100nm. To this end, the embodiment of the present invention has been found through in-depth research that hollow mesoporous silica nanoparticles (HMSN) have a good adsorption effect on the death-related protein kinase 1 inhibitor TC-DAPK6, and no further surface treatment of the carrier is required, and it can be directly used for the preparation of drug-loaded nanoparticles.
[0046] Hollow mesoporous silica nanoparticles are inorganic nanomaterials synthesized with silica as a precursor, and have the characteristics of adjustable mesoporous structure, large specific surface area, stable structure and good in vivo compatibility. Among them, mesopores refer to pores of 2nm to 50nm, and the pore size is preferably 2nm to 15nm, more preferably 2nm to 8nm, and 2nm to 6nm can be used. The diameter of the hollow mesoporous silica nanoparticles used in the embodiment of the present invention is 70nm to 90nm. In order to further increase the drug loading, the specific surface area of the hollow mesoporous silica nanoparticles is 100 to 150m 2 / g.
[0047] In order to realize the positioning, tracking and visualization function of nanoparticles, the carrier of the embodiment of the present invention can further load fluorescent dyes. Fluorescent dyes can be selected from rhodamine B, fluorescein isothiocyanate, etc. Wherein, rhodamine B is a red fluorescent dye with excellent photophysical properties and biocompatibility. At this time, the prepared nanovesicles have multiple effects such as fluorescence imaging, inflammatory targeting and drug treatment at the same time.
[0048] The present invention further provides a method for preparing the nanovesicles, which comprises at least the following steps:
[0049] S1. Dispersing hollow mesoporous silica nanoparticles in an organic solvent, adding death-associated protein kinase 1 inhibitor TC-DAPK6, stirring, separating, washing, and drying to obtain drug-loaded nanoparticles; the mass ratio of the hollow mesoporous silica nanoparticles to the death-associated protein kinase 1 inhibitor TC-DAPK6 is 4 to 1:1, preferably 2 to 1:1;
[0050] S2, separation and acquisition of macrophage membrane;
[0051] S3. The drug-loaded nanoparticles and macrophage membranes are mixed in a buffer solution to obtain a mixed solution, and the mixed solution is extruded through porous membranes with pore sizes of 400 nm and 200 nm in sequence 12 to 18 times using a micro-liposome extruder to obtain nanovesicles.
[0052] As an improvement of the embodiment of the present invention, in S1, at room temperature, the stirring time is 8 to 14 hours and the stirring speed is 500 to 700 rpm. Under this stirring condition, the adsorption of TC-DAPK6 by hollow mesoporous silica nanoparticles can be better achieved.
[0053] As an improvement of the embodiment of the present invention, in S1, the volume of each mg of hollow mesoporous silica nanoparticles dispersed in the organic solvent is 2 to 4 mL, preferably 2.5 mL. If the content of the hollow mesoporous silica nanoparticles in the organic solvent is too much, the drug loading rate is reduced, and if the content of the hollow mesoporous silica nanoparticles in the organic solvent is too little, the yield is reduced.
[0054] As an improvement of the embodiment of the present invention, the organic solvent is selected from anhydrous ethanol. The hollow mesoporous silica nanoparticles have good dispersibility in anhydrous ethanol, TC-DAPK6 and rhodamine B are both soluble in anhydrous ethanol, and TC-DAPK6 is a hydrophobic compound. HMSN can allow the hydrophobic compound to be loaded from a non-aqueous solution into the voids and retained in an aqueous environment.
[0055] As an improvement of an embodiment of the present invention, in S1, hollow mesoporous silica nanoparticles are dispersed in an organic solvent, and death-associated protein kinase 1 inhibitor TC-DAPK6 and a fluorescent dye are added, and the mass ratio of the hollow mesoporous silica nanoparticles, the death-associated protein kinase 1 inhibitor TC-DAPK6 and the fluorescent dye is 2:2:1 to 1:1:1.
[0056] As an improvement of the embodiment of the present invention, in S1, separation is carried out by centrifugation, and the specific conditions of centrifugation are 5000-6000 rpm, centrifugation twice, each time for 10-20 minutes. Cleaning is carried out by anhydrous ethanol for 2-4 times, and drying is carried out at 40-60° C. for 8-12 hours.
[0057] In S3, the porous membrane may be a polycarbonate porous membrane.
[0058] As an improvement of the embodiment of the present invention, in S3, the mass ratio of the drug-loaded nanoparticles to the macrophage membrane is 2:1 to 1:2. The mass ratio of the drug-loaded nanoparticles to the macrophage membrane can specifically be 2:1, 1:1 and 1:2, and is preferably 2:1.
[0059] As an improvement of the embodiment of the present invention, in S3, the extrusion is performed in a buffer solution, and preferably a PBS buffer solution is used. The concentration of the drug-loaded nanoparticles in the buffer solution is 0.5 mg / mL to 1 mg / mL, preferably 1 mg / mL.
[0060] The embodiments of the present invention also relate to the use of the above-mentioned nanovesicles in the preparation of drugs for treating nerve cell damage. The nanovesicles of the embodiments of the present invention have the characteristics of small particle size, low toxicity, good biocompatibility, etc., and have blood-brain barrier permeability and inflammatory microenvironment targeting, and can reduce the inflammatory response and cell apoptosis during nerve cell damage by inhibiting DAPK1. In a further preferred technical solution, the nanovesicles of the embodiments of the present invention also have the technical advantage of strong fluorescence imaging capability.
[0061] The embodiment of the present invention also relates to a brain-targeted preparation containing the above-mentioned nanovesicles. The brain-targeted preparation of the embodiment of the present invention can penetrate the blood-brain barrier and is used for the treatment of brain nerve cell damage.
[0062] Example 1
[0063] This example is used to illustrate the preparation of nanovesicles (MA@RT-HMSN).
[0064] 1. Cell culture
[0065] Mouse mononuclear macrophage cell line (RAW264.7), mouse hippocampal neuron cell line (HT22), and mouse microvascular endothelial cell line (bEnd.3) were all from the ATCC cell bank in the United States and purchased from Wuhan Pusino Life Science Co., Ltd. All three cells were cultured in high-glucose DMEM medium containing 10% fetal bovine serum and 100 U / mL penicillin-streptomycin mixed solution at 37°C and 5% CO. 2 The cells were cultured in a cell culture incubator.
[0066] 2. Preparation and physicochemical characterization of drug-loaded nanoparticles (RT-HMSN)
[0067] Hollow mesoporous silica nanoparticles (HMSN; XFF29, Nanjing Xianfeng Nanomaterials Technology Co., Ltd., with a specific surface area of 133.3 m 2 / g, with a diameter of 70nm to 90nm) as a carrier. Accurately weigh 2 mg of HMSN, add 5 mL of anhydrous ethanol, and disperse it by ultrasound. Then add 2 mg of TC-DAPK6 compound (abbreviated as T) and 1 mg of RhB (abbreviated as R), stir magnetically for 12 hours, collect the drug-loaded nanoparticle mixture, wash it twice with anhydrous ethanol after centrifugation, and dry it in a constant temperature oven at 50°C for 10 hours to obtain a solid sample of drug-loaded nanoparticles RT-HMSN.
[0068] Ultraviolet-visible spectrophotometer (UV-Vis) and high-performance liquid chromatography were used to detect the mass of drugs remaining in the supernatant after the hollow mesoporous nanoparticles were loaded with drugs, and the loading efficiency of rhodamine B and TC-DAPK6 was calculated. The loading rate of hollow mesoporous silica nanoparticles for rhodamine B was 55.9%, and the loading rate for TC-DAPK6 was 53.2%.
[0069] The calculation formula for load efficiency is:
[0070]
[0071] Transmission electron microscopy (TEM) was used to detect the average size of the nanoparticles, Zeta potential analysis was used to determine the potential, and polycrystalline X-ray diffraction (PXRD) was used to confirm the structure and purity of the drug-loaded nanoparticles. Figure 2 , Figure 3 shown.
[0072] 3. Isolation and acquisition of macrophage membrane
[0073] 3.1 Cell culture
[0074] Mouse mononuclear macrophage cell line (RAW264.7), mouse hippocampal neuron cell line (HT22), and mouse microvascular endothelial cell line (bEnd.3) were all from the ATCC cell bank in the United States and purchased from Wuhan Pusino Life Science Co., Ltd. All three cells were cultured in high-glucose DMEM medium containing 10% fetal bovine serum and 100 U / mL penicillin-streptomycin mixed solution at 37°C and 5% CO. 2 The cells were cultured in a cell culture incubator.
[0075] 3.2 Extraction of Macrophage Membranes
[0076] When the RAW264.7 cells are cultured in a culture flask until the degree of confluence reaches more than 90%, the cells are scraped off the culture flask with a plastic cell scraper, and the cells are quickly blown with a pipette to fully disperse the cells to prepare a cell suspension. The cell suspension is aspirated into a centrifuge tube, centrifuged at 1000rpm for 5 minutes, the supernatant is discarded, an appropriate amount of pre-cooled phosphate buffered saline (PBS) is added, and the cells are centrifuged at 600g for 5 minutes at 4°C, the liquid supernatant is removed, and the membrane protein extraction reagent is added to the centrifuge tube, and the cells are fully dispersed by blowing with a pipette, and the cells are placed in an ice bath for 15 minutes. The cell suspension after the ice bath is quickly put into liquid nitrogen, and then thawed at room temperature. This is repeated four times of freezing and thawing. A small amount of sample is taken to detect the degree of cell disruption under a microscope to be greater than 70%. The cell lysate is collected in a centrifuge tube, centrifuged at 700g for 10 minutes at 4°C, and the supernatant is collected in a new centrifuge tube, and centrifuged at 14000g for 30 minutes at 4°C to precipitate and obtain the macrophage membrane.
[0077] To verify that the extracted cells are cell membrane fragments and do not contain other components such as cell nuclei, the cultured RAW264.7 cells were washed once with PBS, fixed with 4% paraformaldehyde for 15 minutes, rinsed twice with PBS, stained with 10μM cell membrane staining solution Dio for 15 minutes, rinsed twice with PBS, stained with cell nucleus staining solution DAPI for 5 minutes, rinsed once with PBS, and then the cell membrane was extracted according to the above steps. After the centrifugal purification step, the extract was observed under a confocal microscope. The experimental results are shown in Figure 2. Figure 1 shown.
[0078] Depend on Figure 1 A shows that after Dio fluorescence staining, the surface of the RAW264.7 cell nucleus is covered with a complete cell membrane structure. Figure 1 As shown in B, after the cell membrane of RAW264.7 cells was extracted after fluorescence staining, green cell membrane fragments with high purity were observed without blue fluorescence of the cell nucleus, indicating that the macrophage membrane was successfully extracted.
[0079] 4. Preparation and physicochemical characterization of MA@RT-HMSN
[0080] The obtained macrophage membrane cell membrane pellet was resuspended in PBS, and RT-HMSN was mixed with macrophage membrane (MA) in a weight ratio of 2:1, with a concentration of 1 mg / mL. The macrophage membrane fragments were extruded through 400nm and 200nm polycarbonate porous membranes 15 times in sequence using a microliposome extruder to obtain macrophage membrane vesicles. Excess vesicles were removed by centrifugation to obtain macrophage membrane-coated nanovesicles (MA@RT-HMSN). The particle size of MA@RT-HMSN was detected by TEM, and the potential of macrophage membrane vesicles and MA@RT-HMSN was determined by Zeta potential analysis. The experimental results are shown in the figure. Figure 2 to Figure 5 shown.
[0081] Figure 2 and Figure 3 The TEM results show that HMSNs are uniform in size, spherical and well dispersed, with an average particle size of about 80nm. The average particle size of RT-HMSNs loaded with RhB and TC-DAPK6 is 87nm. MA@RT-HMSNs coated with macrophage membranes are covered with a transparent film with a thickness of about 8nm.
[0082] Figure 4 Zeta potential analysis results show that the potential of RT-HMSN is higher than that of HMSN, and the potential of RT-HMSN surface after coating with macrophage membrane is closer to the surface potential of macrophage membrane vesicles, further proving that the cell membrane is successfully coated on the surface of RT-HMSN.
[0083] Figure 5The PXRD results show that HMSN has no characteristic diffraction peaks and is an amorphous material, with only broad diffuse peaks at 15° and 35°. Both TC-DAPK6 and RhB have multiple strong diffraction peaks, indicating that both are crystalline, while the crystal diffraction peaks of TC-DAPK6 and RhB in the solid dispersion system RT-HMSN all disappear, indicating that both are highly dispersed in the HMSN material in an amorphous state.
[0084] 5. Membrane protein characterization
[0085] The total protein, cell membrane protein, RT-HMSN and MA@RT-HMSN proteins of RAW264.7 cells were extracted, and the expression of key macrophage membrane proteins F4 / 80 and CD11b in the four groups was detected by western blotting. The protein composition of the four groups was characterized by SDS-PAGE gel electrophoresis followed by Coomassie brilliant blue staining. Figure 6 and Figure 7 shown.
[0086] Figure 6 The results of the protein immunoblotting experiment shown in the figure show that the extracted macrophage membrane and MA@RT-HMSN still retain the expression of characteristic macrophage membrane proteins CD11b and F4 / 80, proving that MA@RT-HMSN retains the function of macrophage membrane.
[0087] Figure 7 The Coomassie Brilliant Blue staining results shown in the figure show that MA@RT-HMSN has the same membrane protein composition as the macrophage membrane, while RT-HMSN does not have any protein components, indicating that the macrophage membrane has no effect on its protein composition after being coated on the RT-HMSN surface by mechanical extrusion.
[0088] Example 2
[0089] This example is used to illustrate the in vitro effects of MA@RT-HMSN:
[0090] 1. Cytotoxicity
[0091] HT22 cells and bEnd.3 cells were cultured in 96-well cell culture plates and cultured with medium containing RT-HMSN and MA@RT-HMSN at concentrations of 0, 5, 12.5, 25, 50, and 100 μg / mL, respectively. After 24 hours, the old medium in the well plate was discarded, and 100 μL of CCK-8 mixture was added to each well. The plates were placed at 37°C and 5% CO. 2 The cells were incubated in a cell culture incubator and the absorbance at 450 nm was measured using an ELISA reader after 2 hours to calculate the cell viability. Figure 8 shown.
[0092] The results of CCK-8 cell viability assay showed that after incubation with RT-HMSN for 24 h, both HT22 cells and bEnd.3 cells showed high cell viability in the concentration range below 100 μg / mL, and the viability of both cells decreased significantly at 100 μg / mL. Figure 8 A and 8B; ANOVA, ***P<0.001). However, even at a concentration of 100 μg / mL, the activity of both cells remained above 80%, indicating that the macrophage-coated MA@RT-HMSN had low cytotoxicity and better biocompatibility ( Figure 8 C and 8D).
[0093] 2. Fluorescence imaging capability
[0094] HT22 cells were cultured and inoculated on 24-well cell slides. The cells were incubated with 25 μg / mL of RT-HMSN and MA@RT-HMSN culture media, respectively. The cell slides were collected at 24, 36, and 48 hours, and the slides were sealed with an anti-fluorescence quencher containing DAPI. The localization and intensity of the red fluorescence signal in the cells were observed using a laser scanning confocal microscope.
[0095] HT22 cells were incubated with RT-HMSN and MA@RT-HMSN at a concentration of 25 μg / mL, and cell slides were collected at 24, 36, and 48 hours. The results of laser scanning confocal microscopy showed that compared with the normal control group ( Fig. 9 Compared with NOR, bright red fluorescence was still visible in the RT-HMSN group and MA@RT-HMSN group after 48 hours of incubation ( Fig. 9 B and Fig. 9 C).
[0096] Compared with the RT-HMSN group, the red fluorescence intensity of the MA@RT-HMSN group was slightly weaker ( Fig.10 As shown; ANOVA, *P<0.05, ***P<0.001), which is due to the surface coating of macrophage membrane.
[0097] 3. Expression of DAPK1 and inflammatory factors
[0098] HT22 cells were cultured and seeded in six-well cell culture plates and divided into three groups:
[0099] ①Normal control group: HT22 cells without any treatment;
[0100] ②Glutamate group: HT22 cells were stimulated with 20 mM glutamate to induce neuronal cell damage;
[0101] ③RT-HMSN+glutamate group: HT22 cells were pretreated with RT-HMSN for 12 hours, and then stimulated with 20 mM glutamate.
[0102] After 24 hours, RNA and protein of the three groups of cells were collected, and the relative expression of dapk1 and inflammatory factors (il-6, il-1β and tnf-α) mRNA was detected by real-time fluorescence quantitative PCR; the expression of DAPK1 protein and inflammasome NLRP3 was detected by western blotting. Figure 11 to Figure 15 shown.
[0103] Exposure of HT22 cells to glutamate can simulate the pathological state of neurons undergoing oxidative stress, excitotoxicity and apoptosis. The cell viability of HT22 cells induced by 20 mM glutamate was significantly reduced and less than 80% ( Fig.11 ; ANOVA, ***P<0.001). When HT22 cells were stimulated with 20 mM glutamate, the expression of DAPK1 at both mRNA and protein levels was significantly increased. However, after 12 hours of pretreatment with RT-HMSN, the expression of DAPK1 at both mRNA and protein levels was significantly decreased ( Fig.12 , Fig.13 , Fig.14 As shown; ANOVA, *P<0.05, **P<0.01, ***P<0.001). After glutamate stimulation, the mRNA expression of inflammatory factors IL-6, IL-1β and TNF-α in HT22 cells was significantly increased, and the protein expression of NLRP3 inflammasome was significantly increased; while RT-HMSN pretreatment could significantly reduce the expression of inflammatory factors and inflammasome ( Fig.12 , Fig.13 and Fig.15 As shown; ANOVA, ***P<0.001).
[0104] These results indicate that RT-HMSN can effectively inhibit DAPK1 and reduce inflammatory responses in vitro.
[0105] 4. Neuronal apoptosis
[0106] HT22 cells were cultured and seeded on a 24-well plate cell slide. The experimental grouping and cell treatment methods were the same as in 2.3. After 24 hours, the old culture medium was discarded, the cells were washed once with PBS, fixed with 4% paraformaldehyde for 30 minutes, washed once with PBS, incubated at room temperature for 5 minutes with PBS containing 0.3% Triton X-100, washed twice with PBS, 50 μL of TUNEL detection solution was added to each well, incubated at 37°C in the dark for 60 minutes, washed three times with PBS, and observed under a confocal microscope after sealing with an anti-fluorescence quencher containing DAPI.
[0107] The results of TUNEL experiments showed that 20 mM glutamate stimulation led to a significant increase in HT22 cell apoptosis, while RT-HMSN pretreatment significantly reduced cell apoptosis ( Fig.16 and Fig.17 As shown; ANOVA, ***P<0.001), indicating that RT-HMSN can alleviate neuronal damage.
[0108] 5. Blood-brain barrier permeability and targeting
[0109] bEnd.3 cells were cultured and inoculated in the upper layer of the transwell chamber of a 24-well plate (the semipermeable membrane pore size of the chamber was 0.4 μm and the diameter was 6.5 mm). 200 μL of complete culture medium was added to the upper layer of the chamber and 600 μL of complete culture medium was added to the lower chamber. The medium was changed every two days. The transendothelial cell resistance value was detected using an EVOM2 transmembrane cell resistance meter. After about 6 to 7 days, the cells reached the required resistance value and an in vitro model of the blood-brain barrier was established. RT-HMSN or MA@RT-HMSN nanoparticles containing the same concentration were added to the upper chamber, and HT22 cells were inoculated in the lower chamber on the cell slide. The cells were stimulated and cultured with complete culture medium and 20 mM glutamate, respectively. The cell slides were collected after 24 hours and observed using a laser scanning confocal microscope after sealing.
[0110] The results of cell co-culture showed that RT-HMSN was similar to the blank control group and could hardly penetrate endothelial cells ( Fig.18 A and 18B), while macrophage membrane-coated nanoparticles can penetrate ( Fig.18 C), indicating that MA@RT-HMSN has the ability to cross the blood-brain barrier in vitro. When stimulated by glutamate, HT22 cells showed a significant decrease in the number of cells per well compared to the RT-HMSN group ( Fig.18 D) and MA@RT-HMSN group without glutamate stimulation ( Fig.18 C), the uptake of MA@RT-HMSN by HT22 cells increased significantly ( Fig.18 E), indicating that MA@RT-HMSN has a targeting effect on macrophage chemokines secreted by HT22 cells.
[0111] Example 3
[0112] This example is used to illustrate the research process of the mass ratio of hollow mesoporous silica nanoparticles, TC-DAPK6 and fluorescent dye:
[0113] Prepared according to the method of Example 1, the difference is:
[0114] Experiment 1: Preparation of hollow mesoporous silica loaded with rhodamine B using different ratios: Take 3 tubes, add 2 mg of HMSN and 5 mL of anhydrous ethanol to each, and after ultrasonic dispersion, add 1 mg, 2 mg, and 3 mg of RhB (abbreviated as R) respectively; stir magnetically for 12 hours, collect the drug-loaded nanoparticle mixture, wash it twice with anhydrous ethanol after centrifugation, dry it in a constant temperature oven at 50°C for 10 hours, and weigh the yields to be 0.7 mg, 1.3 mg, and 1.6 mg respectively.
[0115] Experiment 2: Preparation of hollow mesoporous silica loaded with TC-DAPK6 using different ratios: Take 2 tubes, add 2 mg of HMSN and 5 mL of anhydrous ethanol to each, and after ultrasonic dispersion, add TC-DAPK6 in a mass ratio of 1 mg and 2 mg respectively. Stir magnetically for 12 hours, collect the drug-loaded nanoparticle mixture, wash it with anhydrous ethanol twice after centrifugation, dry it in a constant temperature oven at 50°C for 10 hours, and weigh the yields to be 0.7 mg and 1.2 mg respectively.
[0116] Experiment 3: Preparation of hollow mesoporous silica loaded with TC-DAPK6 and rhodamine B in different ratios: Drug-loaded nanoparticles were prepared according to the method of Example 1, except that 2 mg of hollow mesoporous silica nanoparticles, 2 mg of TC-DAPK6 and 1 mg of rhodamine B were added. After washing, drying and weighing, the yield was 1.7 mg.
[0117] Experiment 4: Preparation of hollow mesoporous silica loaded with TC-DAPK6 and rhodamine B in different ratios: Drug-loaded nanoparticles were prepared according to the method of Example 1, except that 2 mg of hollow mesoporous silica nanoparticles, 1 mg of TC-DAPK6 and 1 mg of rhodamine B were added. After washing, drying and weighing, the yield was 1.3 mg.
[0118] Based on the results of the above experiments, the final choice was: the mass ratio of hollow mesoporous silica: TC-DAPK6: rhodamine B was 2:2:1.
[0119] The above description is only a specific embodiment of the present invention, so that those skilled in the art can understand or implement the present invention. Various modifications to these embodiments will be apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments described herein, but should conform to the widest scope consistent with the principles and novel features disclosed herein.
Claims
1. A nanovesicle, characterized in that: The membrane of the nanovesicle is the cell membrane of macrophages, the inner core of the nanovesicle is drug-loaded nanoparticles, the drug-loaded nanoparticles use hollow mesoporous silica nanoparticles as carriers, and the carriers are loaded with death-related protein kinase 1 inhibitor TC-DAPK6.
2. The nanovesicle according to claim 1, characterized in that The carrier is also loaded with a fluorescent dye, which is selected from rhodamine B or fluorescein isothiocyanate.
3. The nanovesicle according to claim 1, characterized in that The diameter of the nanovesicle is 60nm-150nm; the diameter of the hollow mesoporous silica particles is 70nm-90nm.
4. The method for preparing nanovesicles according to any one of claims 1 to 3, characterized in that: At least the following steps are included: S1, dispersing the hollow mesoporous silica nanoparticles in an organic solvent, adding TC-DAPK6, a death-associated protein kinase 1 inhibitor, stirring, separating, washing, and drying to obtain drug-loaded nanoparticles; wherein the mass ratio of the hollow mesoporous silica nanoparticles to the death-associated protein kinase 1 inhibitor TC-DAPK6 is 4 to 1:1; S2, separation and acquisition of macrophage membrane; S3, mixing the drug-loaded nanoparticles with macrophage membranes in a buffer solution to obtain a mixed solution, and using a micro-liposome extruder to sequentially extrude the mixed solution through porous membranes with pore sizes of 400 nm and 200 nm for 12 to 18 times to obtain the nanovesicles.
5. The preparation method according to claim 4, characterized in that: In S1, the volume of the organic solvent dispersed per mg of the hollow mesoporous silica nanoparticles is 2 mL to 4 mL, The organic solvent is selected from anhydrous ethanol; The stirring time is 8 to 14 hours, and the stirring speed is 500 to 700 rpm.
6. The preparation method according to claim 4, characterized in that: In S1, the hollow mesoporous silica nanoparticles are dispersed in an organic solvent, and a death-associated protein kinase 1 inhibitor TC-DAPK6 and a fluorescent dye are added, wherein the mass ratio of the hollow mesoporous silica nanoparticles, the death-associated protein kinase 1 inhibitor TC-DAPK6 and the fluorescent dye is 2:2:1 to 1:1:
1.
7. The preparation method according to claim 4, characterized in that: In S1, the separation is carried out by centrifugation, the washing is carried out by anhydrous ethanol for 2 to 4 times, and the drying time is 8 to 12 hours.
8. The preparation method according to claim 4, characterized in that: In S3, the mass ratio of the drug-loaded nanoparticles to the macrophage membrane is 2:1 to 1:2; The concentration of the drug-loaded nanoparticles is 0.5 mg / mL to 1 mg / mL.
9. Use of the nanovesicle according to any one of claims 1 to 2 in the preparation of a drug for treating nerve cell damage.
10. A brain targeting preparation, characterized in that: Contains the nanovesicle according to any one of claims 1 to 3.
